IAS Statin Publication
Update Service
The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS will begin this month providing curated update on all publications involving statins as identified in PubMed.
Statin publications have been targeted because of the fundamental role of statins as agents to reduce atherosclerotic cardiovascular disease (ASCVD) risk. The service aims to address the needs of health care professionals globally who manage patients with or at risk of developing ASCVD.
For the Issues, click here
|
|
|
|
last updated: January 18, 2019
|
| From the IAS President's Desk |
|
|
Dr. Akira Yamamoto
1932-2019
Yuji Matsuzawa, Shizuya Yamashita, Raul Santos, Peter Libby
On behalf of the International Atherosclerosis Society (IAS) |
Dr. Akira Yamamoto suddenly passed away after a short illness on January 7, 2019. A notice of his untimely death has reached us and came as a great shock to all of us. We would like to express our heartfelt condolences to the bereaved family.
Dr. Yamamoto was born in Osaka, Japan in 1932. He graduated from Osaka University Medical School in 1955 and he obtained medical degree in 1956. He graduated from Osaka University Graduate School of Medicine and received PhD for the research of lipid metabolism of fatty liver. As a postdoctoral fellow, he studied abroad in the City of Hope National Medical Center, CA, USA and worked on phospholipid metabolism with Prof. George Rouser from 1964 to 1967. After he came back to Japan, he became the Director of Lipid Research Laboratory at the Second Department of Internal Medicine of Osaka University and opened a specific outpatient clinic for patients with hyperlipidemia especially familial hypercholesterolemia (FH).
While he was groping the way of effective treatment of severe FH patients, including FH homozygotes often suffering from heart attack, he came across the report of discovery of an HMG-CoA reductase inhibitor (statin) from fungi by Prof. Akira Endo. Dr. Yamamoto met Prof. Endo and asked him to provide the statin. At that time, the pharmaceutical company Sankyo had not decided to develop the derivative to therapeutic drug because there was a marked species difference in the cholesterol lowering effects and side effects. However, because the patient was very sick due to the progression of coronary artery disease, Dr. Yamamoto decided to apply this new cholesterol lowering agent to both homozygotes and heterozygotes. For the first time in the world, Dr. Yamamoto treated a case of severe homozygous FH with Compactin (a prototype of statins) donated by Prof. Endo in 1978 at the Osaka University Hospital. He demonstrated that ~900 mg/dl of serum total cholesterol in the first homozygous FH case was reduced to ~720 mg/dl after 10 days of treatment with Compactin. Subsequently, he treated a severe case of FH heterozygote with Compactin for life-saving and obtained the reduction of total cholesterol from ~400 mg/dl to ~250 mg/dl and observed the disappearance of bruit in the carotid arteries (Atherosclerosis 35: 259-266, 1980). Dr. Yamamoto is the actually first investigator to use statin to “humans” and without his courageous decision, clinical application of statin must have been delayed.
From 1979 to 1996, he worked in the National Cardiovascular Center Research Institute (Suita, Osaka) as a Vice-Director. He also made a great contribution to the treatment of severe hyperlipidemia by the development of LDL apheresis system in collaboration with Kaneka Co.
From 1996, he served as a clinician for the aged patients at Mino City Health Center for the Elderly and at the same time he was still working on the research of lipid metabolism and atherosclerosis as an Honorable Investigator of National Cardiovascular Center.
He acted as a Board Member (Member-at-Large) of the International Atherosclerosis Society (IAS). He was also one of the founding members of Asian-Pacific Society of Atherosclerosis and Vascular Disease (APSAVD). He also used to be the President of International Society for Apheresis.
The vivid impression he made on all of us will always live in our memory.
Address for correspondence: Yuji Matsuzawa, Sumitomo Hospital, Osaka, Japan
E-mail: matsuzawa-yuji@sumitomo-hp.or.jp
|
| Non-Member IAS Endorsed Activities |
|
2nd Severe FH Course: Recognize, Diagnose, and Treat
Severe Familial Hypercholesterolemia (Muscat, Oman, December 2-3, 2018) |
|
Raul Santos (President-Elect, IAS) and Khalid Al-Rasadi (President, OSLA) and was organized by the International Atherosclerosis Society (IAS), the Oman Society of Lipid and Atherosclerosis (OSLA), and the Gulf Heart Association Lipid Working Group (GHALWG). This interactive Course was accredited by the Oman Medical Specialty Board (OMSB) and was open to physicians practicing in the MENA Region.
IAS, OSLA, and GHALWG are happy to announce that the following material presented during the Course are available to our readers:
Scientific Program
Slide Library
Exclusive Interviews: Dr. Khalid AL-RASADI, Dr. Marcello ARCA, Dr. Raul SANTOS, Dr. Hani SABBOUR and Dr. Wolfgang RAMLOW
|
|
IAS-FH Foundation Partnership
Announcing the IAS FH Foundation Partnership
FH Awareness Media Kit by the FH Foundation
FH Foundation - Consensus Statement on Genetic Testing for FH - 2018
The FH Foundation announced that an important consensus statement on diagnosing familial hypercholesterolemia (FH), a common life-threatening genetic condition, was published online in the Journal of the American College of Cardiology. Authored by an international panel of 30 cardiovascular, lipid, genetics and advocacy experts and led by the FH Foundation, the statement recommends that genetic testing be offered to diagnose both individuals with FH and their relatives. FH genetic mutations lead to heart disease and stroke risk during the prime of life. Genetic testing of at-risk individuals holds the promise of accelerating the identification of over 30 million people worldwide born with FH, 90 percent of whom are currently undiagnosed, to ensure early treatment. Read more here.
IAS/FHFo Joint Session on “Recognize Familial Hypercholesterolemia and Save Lives“ during the WCC 2018 Congress (Dubai, UAE, December 8, 2018)
View the Slide Library IberoAmerican FH Network - Mona Lisa Video
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel” - 2016
The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.
New Data on Familial Hypercholesterolemia in Brazil - 2017
ScreenPro - Screening Project for Familial Hypercholesterolemia in Central, Southern, and Eastern Europe
The ScreenPro FH Project started in 2014/2015. Based on the Czech MedPed experience the project was established for screening, diagnosis and treatment of FH patients in the region of Central, Eastern and Southern Europe.
- We started with 8 countries, now we are 20.
- We started with 70 centers, now we are 181 (other 40 in development).
- We started with 7500 patients in the local databases, now, they are 23 191.
- We started cooperation with patient´s organization in 8 countries (2017).
- We focus on education, screening and care of FH patients. Nowadays we are on the way from description of the situation to improvement in the treatment.
You can view it here and here
News from the Iraqi Lipid Clinics Network
The success story deriving from the educational activities of the IAS and OSLA in the MENA Region continues. Thanks to the efforts of Dr. Mutaz Alkhnifsaw and his Iraqi colleagues at the moment 8 Lipid clinics have been established throughout the country.
- NEW EDUCATIONAL INITIATIVE “FH AMBASSADOR MISSION”
Dr. Mutaz Al-khnifsawi, president of the Iraqi Lipid Clinics Network, participated recently in a workshop held in Cairo, Egypt. The participants were a group of Egyptian university students, newly graduated males and females, as well as some Iraqis living in Egypt.
The workshop focused on Familial hypercholesterolemia/FH (prevalence, risk, how to diagnose, how to treat, the importance of early detection and cascade screening) is part of the IAS-OSLA campaign, established in Iraq several months ago to raise public awareness about Familial hypercholestrolemia, The presentations by dr Mutaz used a simplified language to better transfer the messages and included short videos and also photos of FH signs. A stimulating and interactive discussion followed the presentations.
Dr. Mutaz Al-khnifsawi, participated recently in the FH Global Summit in Los Angeles, CA, USA and delivered an FH awareness lecture about the prevalence, risk, importance of early diagnosis and cascade screening for some Iraqis and middle east people living in California, USA in their mosque after the night pray time was given.
- OUR CELEBRATION IN FH AWARENESS DAY
In September 24th 2018, The Iraqi lipid clinics network celebrated the FH awareness day in which a sample from the Iraqi people in Al-Diwaniya city 200 km to the South of the Capital Baghdad include various layers of the community (Solider, Engineer, University Students, Journalists, Doctor and Pharmacist, Nursing Staff, Educational Staff in Schools, University Professors) met together to listen to our talk about FH (Prevalence, risk, signs of the disease, the importance of early diagnosis and cascade screening of the family) in a simplified native language that included photos and short videos illustrating the impact of the problem.
This event was followed by Radio broadcast in the local radio station of the city that was published on social media which talk to the whole Iraqi people about FH.
Dr Mutaz Al-khnifsawi, President of the Iraqi Lipid Clinics Network and Dr Mohammed Asamawa, Secretary of the Iraqi Lipid Clinics Network have been very active in rising awareness on familial lipid disorders among the Iraqi medical community and the population.
- NEWS FROM OSLA
The SAFEHEART Registry
Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.
You can view it here
E-Learning cor2ed
Improving management through genetic testing for Familial Hypercholesterolaemia (FH)
This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:
- Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
- How and why to use genetic testing
- How to interpret results
- How to use cascade screening to identify related individuals at risk
You can view the e-learning at https://checkpoint.cor2ed.com/
Severe FH Course “Identifying and Treating Severe Familial Hypercholesterolemia” (Dubai, UAE, October 14-15, 2017)
The International Atherosclerosis Society (IAS), the Oman Society of Lipid and Atherosclerosis (OSLA), the Gulf Heart Association (GHA), and the Emirates Cardiac Society (ECS), are happy to make available to our readers some important documents related to the Course on Identifying and Treating Severe Familial Hypercholesterolemia which
was held in Dubai, UAE on October 14-15, 2017. The Course was co-chaired by Profs. Raul Santos (President-Elect of IAS), Khalid Al-Rasadi (President, OSLA) and Wael Almahmeed (Board Member of GHA).
We would love to hear from our member societies about other such exciting and important successes in the field throughout the world and look forward to hearing from you.
|
| XX International Atherosclerosis Society 2024 - Winner |
We are pleased to announce that after the presentation of the outstanding bids for the ISA2024 Symposium from the Russian National Atherosclerosis Society (RNAS), Emirates Cardiac Society (ECS), Lipid Association of India (LAI), and Oman Society of Lipids & Atherosclerosis (OSLA) the IAS Executive Board during its meeting held in Toronto on June 9 has selected the winner of the ISA2024: the Oman Society of Lipids and Atherosclerosis (OSLA).
|
| IAS - OSLA Collaboration in the MENA Region |
The International Atherosclerosis Society (IAS) and Oman Society of Lipid & Atherosclerosis (OSLA) are organizing the Fifth IAS-OSLA Course "Lipid Metabolism and Cardiovascular Risk" to be held in Muscat, Oman, on February 8-11, 2019.
As in 2015, 2016, 2017 and 2018, the aim of this Course is to increase the knowledge and experience of early- to mid-career, English-speaking practicing clinicians interested in the management of lipid disorders and will be restricted to 30 clinicians practicing in the Middle East and North Africa (MENA) region who manage patients with lipid disorders.
Who can apply: Clinicians (including adult or pediatric cardiologists, endocrinologists, general practitioners, lipidologists, clinical biochemists) below the age of 40 years who are currently working at a hospital/university/other health institute in the MENA region.
If you are interested in participating, you must apply before January 1st, 2019. Notifications will be sent by January 6, 2019.
Please send your application to: oslaoman@gmail.com
For more information please link to the flyer of the Course
|
| Meeting and Educational Activity Highlights |
To view all highlights, please click here
|
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Amryt, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Kaneka Europe, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
|
Disclaimer - Cookie policy
This site is optimised for a min. 1024 x 768 pixels resolution
|
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|
|
| IAS Newsletter Editors & Website Editorial Board |
Editor-in-Chief
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Associate Editors
Stefano Bellosta
Milan, Italy
Emanuela Folco
Milan, Italy
Ann Jackson
Houston, TX, USA
Commentary & Newsletter Editor
Yelonda Williams
(Dallas, TX, USA)
Elena Colombo
(Milan, Italy)
|
|
|
